Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Food Addiction in Obesity
NCT03431831Phase 4Completed
- Sponsor
- University of Nebraska
- Start
- Jul 2017
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of naltrexone + bupropion in obesity (4 arms), sponsored by University of Nebraska. Primary endpoints: Weight at 6 months and Body Mass Index at 6 months. Started Jul 2017; status: completed.
02
Drugs
naltrexone + bupropion
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03431831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03431831.